Bell Potter facing class action
A class action has been initiated in the Federal Court by 50 former clients of Bell Potter Securities over the company’s alleged conduct with respect to the purchase of shares in a Brisbane biotechnology company, Progen Pharmaceuticals.
The former clients are being represented by law firm Slater & Gordon, which has said it will be alleged to the court that Bell Potter manipulated the market in Progen shares and engaged in misleading and deceptive conduct when it encouraged clients to buy the overvalued shares ahead of and subsequent to Bell Potter being a co-underwriter of a Progen capital raising.
Slater and Gordon solicitor Van Moulis said it was being alleged in the class action that reports published by Bell Potter analysts improperly inflated the value of Progen stock and were then used by brokers to promote the stock to clients.
He said investors were seeking compensation from Bell Potter for their share trading losses, legal costs plus interest.
Bell Potter has indicated it will be vigorously defending the claim.
AUTHOR
Mike Taylor
Recommended for you
Clime’s disposal of advice licensee Madison “needed to happen yesterday”, managing director Michael Baragwanath has told Money Management, as he concludes a severe cost-out period at the business.
As Viola Private Wealth continues on its growth trajectory, the wealth management firm has appointed a seasoned investment professional to be its first chief investment officer.
Financial advisers who wish to implement artificial intelligence in their practices need to undergo a change in their mindset as to how they use technology.
With United Global Capital expected to constitute a substantial portion of CSLR compensation in FY25–26, what has AFCA ruled in its determinations on the company so far?
